Inventor · disambiguated record
Edward Pierson
Also filed as: PIERSON EDWARD
4 granted patents·11 pending applications·33 citations·filing 2002–2009
75Inventor score
Top patents by PatentIndex Score
15 records- 0182US6812225B2Therapeutic heterocyclic compoundsASTRAZENECA AB·Filed 2002·Granted Nov 2, 2004·16 cites·9 claims
- 0274US7045514B2Therapeutic heterocyclic compoundsASTRAZENECA AB·Filed 2004·Granted May 16, 2006·6 cites·12 claims
- 0374US7026314B2Therapeutic chromone compoundsASTRAZENECA AB·Filed 2002·Granted Apr 11, 2006·10 cites·52 claims
- 0473US7285662B2Therapeutic heterocyclic compoundsASTRAZENECA AB·Filed 2005·Granted Oct 23, 2007·1 cites·6 claims
- 0560US2008076759A1Therapeutic Heterocyclic Compounds 507ASTRAZENECA AB·Filed 2007·Application pending·0 cites
- 0656US2009170851A1Chroman CompoundsBERNSTEIN PETER·Filed 2009·Application pending·0 cites
- 0751US2007185107A1Chroman compoundsASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 0850US2006178372A1Therapeutic quinoline compoundsASTRAZENECA AB·Filed 2006·Application pending·0 cites
- 0945US2009004106A1Radioligands for the 5 -Ht1b ReceptorHEYS JOHN RICHARD·Filed 2007·Application pending·0 cites
- 1045US2005096312A1Therapeutic quinolone compounds with 5-ht-antagonistic propertiesFiled 2002·Application pending·0 cites
- 1142US2006019947A1Therapeutic chromone compoundsCHAPDELAINE MARC·Filed 2005·Application pending·0 cites
- 1239US2005085457A1Therapeutic quinolone compounds with 5-ht-antagonistic propertiesFiled 2002·Application pending·0 cites
- 1339US2007010526A1Therapeutic isoquinoline compoundsHAEBERLEIN MARKUS·Filed 2002·Application pending·0 cites
- 1436US2004082591A1Therapeutic heterocyclic compoundsFiled 2002·Application pending·0 cites
- 1536US2004110745A1Therapeutic chroman compoundsFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Edward Pierson files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →